Abstract
Tumour necrosis factor (TNF) is the dominant mediator of the cytokine cascade that causes inflammation and joint detruction in rheumatoid arthritis. A new class of agents under investigation, the biological TNF inhibitors, inhibit the activity of TNF. Recombinant human TNF receptor p75 Fc fusion protein (TNFR:Fc; etanercept) blocks the activity of the cytokine TNF. The preclinical and pivotal trials evaluating etanercept in rheumatoid arthritis are reviewed in this article.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have